Editor's Note: When it comes to big biotech gains, few people are better qualified than Brownstone Research analyst Jeff Brown. Some of his recent biotech plays soared as high as 432%, 162%, and 332%. And Jeff's next opportunity is setting up to be even bigger. Dear Reader, I wanted to send you a quick note before I wrap things up for Christmas… I'm afraid we're running out of time… For months, I've been pounding the table on a tiny biotech company… They are sitting on what could be the biggest antibiotic breakthrough of the last 30 years. In fact, the FDA just fast-tracked the approval of this new drug… And I believe it's just a matter of time before this stock takes off — as much as an extraordinary 1,200% within hours. This might be your last chance before it's too late. Click here to get the details. Here's to a great 2021, Jeff Brown
Founder, Brownstone Research P.S. Similar breakthroughs sent shares of tiny biotech companies through the roof: - Agios Pharmaceuticals: +740%
- MyoKardia: +884%
- G1 Therapeutics: +442%
- Regenxbio: +894%
- Clovis Oncology: +585%
- Karuna Therapeutics: +629%
- Amarin: +733%
- Agile Therapeutics: +1,086%
I expect this one to be no different. But you have to act now — before it's too late. Go here to learn more. | 
No comments:
Post a Comment